ClinicalTrials.gg
CompletedNCT03109327OMS002_UKUpdated Nov 19, 2020

Investigating the Clinical Utility of the MDS

An observational study in Skin Lesion, Melanoma and Moles, sponsored by Orlucent, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-11-19.

Sponsored by Orlucent, Inc · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 269 studies in Melanoma with a site in United Kingdom — 31 open to participants now, 73 under way, 24 of them phase 3. Melanoma · United Kingdom.

Enrollment
27th of 41
250 · median 400
Started
2018
with 15 others
Observational
41 of 269
9 open now
Registered
137th of 269
by date

Among the 269 studies in Melanoma with a site in United Kingdom, this one is the 27th largest by enrollment of the 41 observational ones that give a count, is one of 16 that started in 2018, is one of 41 observational ones, and was the 137th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

31 of the 269 studies in Melanoma with a site in United Kingdom are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 269 studies in Melanoma with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to establish the clinical utility of the Melanoma Detection System (MDS).

Read the detailed description

The purpose of this study is to establish the clinical utility of the MDS while continuing to evaluate the safety and performance of the MDS in patients with skin lesions who are referred to secondary care clinics for evaluation, whose lesions (moles) are suspicious for melanoma.

03

Conditions studied

  • Skin Lesion
  • Melanoma
  • Moles

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects referred to a specialist for possible presence of melanoma in skin lesions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Lesion has one or more of the ABCDE features and is recommended for excision.
  2. Lesion has at least 1 cm of skin around it that is accessible to the MDS.
  3. Patient is at least 18 years old.
  4. Patient is capable of giving written .
  5. Lesion is scheduled for primary excision.

Exclusion criteria

Exclusion Criteria:

  1. Lesion is less than one centimetre from the eyes.
  2. Lesion is on the palms of the hands or soles of the feet.
  3. Lesion is mucosal.
  4. Lesion is ulcerated.
  5. Patient is pregnant.
  6. Low patient study procedure compliance.
  7. Patient who is mentally or physically unable to comply with all aspects of the study.
  8. Patient is undergoing chemotherapy.
  9. Patient has known sensitivity to fluorescent dyes.
  10. Ink marking on or adjacent to lesion.
  11. Lesions larger than 20mm or too large to allow imaging.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (actual)
Patient registry
No

Groups and cohorts

  • Urgent Excision

    Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.

    Diagnostic Test: Melanoma Detection System -MDS

  • Non-urgent Excision

    Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.

    Diagnostic Test: Melanoma Detection System -MDS

Interventions

  • Diagnostic testMelanoma Detection System -MDS

    Imaging of lesion using the MDS test.

    Also known as: MDS

06

What researchers measure

Primary outcomes

  1. Utility of the MDS in determining urgent or non-urgent excision of moles.

    The MDS will provide a score that reflects the possibility for the presence of melanoma in moles. The score will be used together with clinical evaluation.

    Time frame: 1 day

Secondary outcomes

  1. Does the MDS have an additive value to clinical evaluation of moles.

    Does the MDS system provide superior results when compared to clinical evaluation.

    Time frame: 1 day

Other outcomes

  1. User feedback for clinical use of the MDS in the clinical management of moles.

    To gain feedback from users on how to best incorporate the MDS testing procedure in the clinical setting.

    Time frame: 1 day

07

Study locations

1 site
  • NHS Lanarkshire, Monklands Hospital
    Airdrie, ML60JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Oct 2020, 30 months.

Of 59 industry-sponsored observational studies under Melanoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 80. This study's 30 months is below that.

Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2017
First posted
Apr 12, 2017
StartActual
Apr 1, 2018
Primary completionActual
Oct 30, 2020
CompletionActual
Oct 30, 2020
Last update
Nov 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03109327
Lead sponsor
Orlucent, Inc
Collaborators
NHS Lanarkshire, NHS Tayside, NHS Greater Glasgow and Clyde, University Hospitals, Leicester, University of Dundee
Responsible party
Sponsor
First posted
Apr 12, 2017
Start date
Apr 1, 2018
Primary completion
Oct 30, 2020
Completion
Oct 30, 2020
Last update
Nov 19, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion